MARKET

CHMA

CHMA

Chiasma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.010
-0.010
-0.25%
After Hours: 4.010 0 0.00% 16:00 05/14 EDT
OPEN
4.000
PREV CLOSE
4.020
HIGH
4.125
LOW
3.930
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
2.770
MARKET CAP
232.16M
P/E (TTM)
-2.5041
1D
5D
1M
3M
1Y
5Y
Acentrus Specialty Contracts with Chiasma to Bring MYCAPSSA(R) (octreotide) to Health Systems and Hospitals in the Acentrus Network
Acentrus Specialty(TM), a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Chiasma, Inc. (NASDAQ: CHMA) to provide qualified Acentrus clients access to MYCAP...
BusinessWire · 1d ago
Chiasma (CHMA) is Overbought: Is A Drop Coming?
Zacks.com · 1d ago
Global Acromegaly Treatment Market Size, Share, Value, and Competitive Landscape 2020
May 12, 2021 (Heraldkeepers) -- The Acromegaly Treatment market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 2d ago
Acromegaly Treatment Market Detailed Competitive Outlook by 2028
May 12, 2021 (AmericaNewsHour) -- Research Nester published a report titled “Acromegaly Treatment Market: Global Demand Analysis & Opportunity Outlook...
AmericaNewsHour · 2d ago
CECE, CCXI, CNDT and KDMN among after-hours movers
Gainers: [[CECE]] +4.3%. [[CCXI]] +4.2%. [[SVC]] +3.6%. [[GTX]] +3.0%. [[BBGI]] +3.0%.Losers: [[CNDT]] -2.9%. [[KDMN]] -2.4%. [[CHMA]] -2.0%. [[ISBC]] -2.0%. [[VBLT]] -1.9%.
Seekingalpha · 6d ago
Chiasma, Inc. to Host Earnings Call
May 06, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Chiasma, Inc. (NASDAQ:CHMA) will be discussing their earnings results in...
ACCESSWIRE · 05/06 18:50
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 11:49
30 Stocks Moving in Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 94.2% to $2.33 in pre-market trading. Stealth BioTherapeutics showcased data for Elamipretide in dry age-related macular degeneration at the 2021 ARVO Annual Meeting.
Benzinga · 05/06 11:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHMA. Analyze the recent business situations of Chiasma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHMA stock price target is 9.10 with a high estimate of 18.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 41.25M
% Owned: 71.26%
Shares Outstanding: 57.89M
TypeInstitutionsShares
Increased
31
3.64M
New
14
959.24K
Decreased
22
3.63M
Sold Out
12
2.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.42%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
David Stack
President/Chief Executive Officer/Director
Raj Kannan
Chief Financial Officer/Senior Vice President/Treasurer
John Doyle
Executive Vice President
Anand Varadan
Executive Vice President
anand Varadan
Senior Vice President
William Ludlam
Chief Accounting Officer/Vice President - Finance/Vice President - Administration
Drew Enamait
Vice President/General Counsel/Secretary
Lee Giguere
Director
Roni Mamluk
Independent Director
Todd Foley
Independent Director
Bard Geesaman
Independent Director
Scott Minick
Independent Director
John Scarlett
Independent Director
John Thero
No Data
About CHMA
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Webull offers kinds of Chiasma Inc stock information, including NASDAQ:CHMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHMA stock methods without spending real money on the virtual paper trading platform.